Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  The Lancet

• Publication date

  2003-11-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(03)14738-1PMID 14615106
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

  2018cited by this paper
• Anticonvulsant drugs for acute and chronic pain.

  2010cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

  2004cited by this paper
• Cannabis Use as Described by People with Multiple Sclerosis

  2003cited by this paper
• Cannabis and the brain.

  2003cited by this paper
• Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles (3rd Edition)

  2003cited by this paper
• Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

  2003cited by this paper
• Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

  2003cited by this paper
• Anti-spasticity agents for multiple sclerosis.

  2003cited by this paper
• A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

  2003cited by this paper
• Cannabinoids in MS: potentially useful but not just yet!

  2002cited by this paper
• Measurement of neurological outcomes

  2002cited by this paper
• Safety, tolerability, and efficacy of orally administered cannabinoids in MS

  2002cited by this paper
• An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

  2001cited by this paper
• Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review

  2001cited by this paper
• Utilization of unconventional treatments by persons with MS: Is it alternative or complementary?

  1999cited by this paper
• The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis

  1999cited by this paper
• Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.

  1998cited by this paper
• The perceived effects of smoked cannabis on patients with multiple sclerosis.

  1997cited by this paper
• Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms.

  1996cited by this paper
• Urodynamics and multiple sclerosis.

  1996cited by this paper
• Short‐term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers

  1994cited by this paper
• Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double‐blind, placebo‐controlled trial

  1994cited by this paper
• Inter-rater reliability of the Ashworth scale in multiple sclerosis

  1994cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper
• The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment.

  1991cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.

  1988cited by this paper
• A user's guide to the General Health Questionnaire

  1988cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Treatment of Human Spasticity with Δ9‐Tetrahydrocannabinol

  1981cited by this paper
• Treatment of human spasticity with delta 9-tetrahydrocannabinol.

  1981cited by this paper
• A treatment allocation procedure for sequential clinical trials.

  1980cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper
• PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

  1964cited by this paper

• Nabiximols improves sleep architecture in multiple sclerosis: A prospective polysomnographic study.

  2026cites this paper
• Cannabis-based medicines for chronic neuropathic pain in adults.

  2026cites this paper
• Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks

  2025cites this paper
• Therapeutic Use of Cannabis and Cannabinoids: A Review.

  2025cites this paper
• Therapeutic cannabis: Knowledge, uses, and expectations of Moroccan neurologists in their professional practice for the management of multiple sclerosis

  2025cites this paper
• High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review.

  2025cites this paper
• Exploring therapeutic potential of Cannabis based therapy in autoimmune and rheumatic disorders.

  2025cites this paper
• Cannabinoids for Treating Sleep

  2025cites this paper
• Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy

  2025influential citation
• ATTITUDES AND PRACTICE PATTERNS OF CANADIAN PHYSIATRISTS REGARDING MEDICAL CANNABIS

  2025cites this paper
• Cannabinoid 1 receptor occupancy and neurovascular responses induced by agonist, antagonist/inverse-agonist, and potential modulator in non-human primate brains: PET/fMRI study.

  2025cites this paper
• Narrative bias ("spin") is common in randomised trials and systematic reviews of cannabinoids for pain.

  2024cites this paper
• Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine

  2024cites this paper
• Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference

  2024cites this paper
• Inpatient dronabinol utilisation: an institutional retrospective study to determine prevalence and indications for clinical application.

  2024cites this paper
• Efficiency of cannabis and cannabidiol in managing chronic pain syndromes: A comprehensive narrative review.

  2024cites this paper
• Exploring the efficacy of cannabinoids in the management of multiple sclerosis

  2024cites this paper
• Quantification and time course of subjective psychotropic and somatic effects of tetrahydrocannabinol – a prospective, single-blind, placebo-controlled exploratory trial in healthy volunteers

  2024cites this paper
• Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation

  2024cites this paper
• Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials

  2024cites this paper
• The Development of Cannabinoids as Therapeutic Agents in the United States

  2024cites this paper
• Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

  2024cites this paper
• A recent update on the antibacterial effects of distinct bioactive molecules derived from the Cannabis plant

  2024cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update—Surveillance Report 4

  2023cites this paper
• Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases

  2023cites this paper
• Managing the Symptoms of Multiple Sclerosis

  2023cites this paper
• Nociceptive and Mixed Pain Syndromes in Patients with Multiple Sclerosis

  2023cites this paper
• Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns

  2023cites this paper
• Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies

  2023cites this paper
• Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis

  2023influential citation
• Role of omega-3 endocannabinoids in the modulation of T-cell activity in a multiple sclerosis experimental autoimmune encephalomyelitis (EAE) model

  2023cites this paper
• Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance

  2023cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update—Surveillance Report 3

  2023cites this paper
• Effect of Cannabidiol on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells

  2023cites this paper
• Reactive nitrogen species as therapeutic targets for autophagy/mitophagy modulation to relieve neurodegeneration in multiple sclerosis: Potential application for drug discovery.

  2023cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update—Surveillance Report 2

  2023cites this paper
• Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions

  2023cites this paper
• Effects of Cannabidiol Interactions with CYP2R1, CYP27B1, CYP24A1, and Vitamin D3 Receptors on Spatial Memory, Pain, Inflammation, and Aging in Vitamin D3 Deficiency Diet-Induced Rats

  2022cites this paper
• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

  2022cites this paper
• Thromboembolic Outcomes in Tetrahydrocannabinol-Positive Trauma Patients With Traumatic Brain Injury.

  2022cites this paper
• Pharmacological treatment of tremor in multiple sclerosis; a systematic review.

  2022cites this paper
• Cannabis and Cannabinoids in Multiple Sclerosis: From Experimental Models to Clinical Practice—A Review

  2022cites this paper
• The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials

  2022cites this paper
• [Nociceptive and mixed pains in patients with multiple sclerosis].

  2022cites this paper
• Angiogenesis and Multiple Sclerosis Pathogenesis: A Glance at New Pharmaceutical Approaches

  2022cites this paper
• Online survey of medicinal cannabis users: Qualitative analysis of patient-level data

  2022cites this paper
• Sistema endocannabinoide y el rol del cannabis medicinal en el tratamiento de la espasticidad: una revisión narrativa

  2022cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 4

  2022cites this paper
• Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry

  2022cites this paper
• Pathogenesis and management of multiple sclerosis revisited.

  2022cites this paper
• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 1, September 2022

  2022cites this paper
• Cannabinoids: Legal aspects, pharmacology, phytochemistry, probable targets from biological system, and therapeutic potential

  2022cites this paper
• Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  2022cites this paper
• A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis

  2022cites this paper
• Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?

  2022cites this paper
• Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population.

  2022cites this paper
• Ten reasons to consider cannabinoids in everyday clinical practice

  2022cites this paper
• Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

  2022cites this paper
• The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

  2022influential citation
• Cannabis and cannabinoid use in autism spectrum disorder: a systematic review

  2021cites this paper
• The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial

  2021cites this paper
• Cerebellar Contributions to Motor Impairments in People with Multiple Sclerosis

  2021cites this paper
• Safety of Medical Cannabis in Neuropathic Chronic Pain Management

  2021influential citation
• Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline

  2021cites this paper
• Medical Cannabis and Cannabinoids for Impaired Sleep: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

  2021cites this paper
• Interpretation of vaccine associated neurological adverse events: a methodological and historical review

  2021cites this paper
• Cannabinoids in Neurologic Illnesses.

  2021cites this paper
• Effect of inhibitory kinesiotaping on spasticity in patients with chronic stroke: a randomized controlled pilot trial

  2021cites this paper
• Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials

  2021influential citation
• Le système de signalisation endocannabinoïde: structure, fonction, pharmacologie

  2021cites this paper
• Approved cannabinoids for medical purposes - Comparative systematic review and meta-analysis for sleep and appetite.

  2021cites this paper
• The Diels‐Alder Approach towards Cannabinoid Derivatives and Formal Synthesis of Tetrahydrocannabinol (THC)

  2021cites this paper
• Cannabinoid Activity—Is There a Causal Connection to Spasmolysis in Clinical Studies?

  2021cites this paper
• Cannabis-Induced Neuroactivity: Research Trends and Commercial Prospects

  2021cites this paper
• Cannabidiol and Other Cannabinoids in Demyelinating Diseases

  2021cites this paper
• Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis

  2021cites this paper
• Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland

  2021cites this paper
• Patterns of Medical Cannabis Use among Patients Diagnosed with Multiple Sclerosis.

  2021cites this paper
• Assessment of hemp oil-based cannabidiol use in a community-based pharmacy setting.

  2021cites this paper
• Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues.

  2021cites this paper
• The Neuroprotective properties, Functions and Roles of Cannabis sativa in selected diseases related to the Nervous System.

  2021cites this paper
• Neurodegenerative

  2021cites this paper
• Cannabinoids and Neuropsychiatric Disorders

  2021influential citation
• The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis

  2021cites this paper
• Medical Cannabis in Children and Adolescents in Switzerland: a Retrospective Study

  2021cites this paper
• Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older

  2021influential citation
• Cannabinoids in Neurologic Conditions

  2020cites this paper
• How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?

  2020cites this paper
• Cannabis (Marijuana) and Cannabinoids

  2020cites this paper
• Exploring the immunosuppressive properties of various agents in the experimental autoimmune encephalomyelitis models of multiple sclerosis

  2020cites this paper
• Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain

  2020cites this paper
• Vitamin C ameliorates tetrahydrocannabinol-induced spermatotoxicity in-vitro

  2020cites this paper
• Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders

  2020cites this paper
• Tremor in Multiple Sclerosis—An Overview and Future Perspectives

  2020cites this paper
• Multiple Sklerose: Therapie

  2020cites this paper
• Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review.

  2020cites this paper
• An Agathokakological tale of ∆9 -THC: Exploration of Possible Biological Targets.

  2020cites this paper
• Cannabis and Multiple Sclerosis.

  2020cites this paper
• Minimally Invasive Surgery for Chronic Pain Management: An Evidence-Based Approach

  2020cites this paper
• Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology

  2020cites this paper